News | December 30, 2021
Sanofi loses appeal in the US over Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Go-ahead for pivotal clinical trial which is expected to commence by March
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Biocon Biologics and Viatris co-developed the products
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
